Tivic Health Systems Inc. has announced a significant expansion in its manufacturing capabilities following the acquisition of certain CDMO assets, now branded as Velocity Bioworks. This move has enabled Tivic to achieve a 200-fold scale-up in the production of its lead drug candidate, Entolimod, a TLR5 agonist under development for Acute Radiation Syndrome (ARS) and Neutropenia. The company has successfully demonstrated commercial-scale production and is preparing to initiate manufacturing under current Good Manufacturing Practice (cGMP) conditions, marking a key step toward filing a Biologics License Application with the FDA. The expansion is expected to enhance operational and cost efficiencies and accelerate the path to commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126283) on January 12, 2026, and is solely responsible for the information contained therein.